Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Anti-tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC-dependent vulnerability.

Iwai K, Yaguchi M, Nishimura K, Yamamoto Y, Tamura T, Nakata D, Dairiki R, Kawakita Y, Mizojiri R, Ito Y, Asano M, Maezaki H, Nakayama Y, Kaishima M, Hayashi K, Teratani M, Miyakawa S, Iwatani M, Miyamoto M, Klein MG, Lane W, Snell G, Tjhen R, He X, Pulukuri S, Nomura T.

EMBO Mol Med. 2018 May 16. pii: e8289. doi: 10.15252/emmm.201708289. [Epub ahead of print]

2.

Antitumor activity of kinetochore-associated protein 2 siRNA against lung cancer patient-derived tumor xenografts.

Makita Y, Teratani M, Murata S, Hoashi Y, Matsumoto S, Kawamata Y.

Oncol Lett. 2018 Apr;15(4):4676-4682. doi: 10.3892/ol.2018.7890. Epub 2018 Jan 29.

3.

Anti-tumor activity of KNTC2 siRNA in orthotopic tumor model mice of hepatocellular carcinoma.

Makita Y, Murata S, Katou Y, Kikuchi K, Uejima H, Teratani M, Hoashi Y, Kenjo E, Matsumoto S, Nogami M, Otake K, Kawamata Y.

Biochem Biophys Res Commun. 2017 Nov 4;493(1):800-806. doi: 10.1016/j.bbrc.2017.08.088. Epub 2017 Aug 23.

4.

In Vivo Knockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs).

Ohoka N, Okuhira K, Ito M, Nagai K, Shibata N, Hattori T, Ujikawa O, Shimokawa K, Sano O, Koyama R, Fujita H, Teratani M, Matsumoto H, Imaeda Y, Nara H, Cho N, Naito M.

J Biol Chem. 2017 Mar 17;292(11):4556-4570. doi: 10.1074/jbc.M116.768853. Epub 2017 Feb 2.

5.

Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles.

Sugo T, Terada M, Oikawa T, Miyata K, Nishimura S, Kenjo E, Ogasawara-Shimizu M, Makita Y, Imaichi S, Murata S, Otake K, Kikuchi K, Teratani M, Masuda Y, Kamei T, Takagahara S, Ikeda S, Ohtaki T, Matsumoto H.

J Control Release. 2016 Sep 10;237:1-13. doi: 10.1016/j.jconrel.2016.06.036. Epub 2016 Jun 29.

PMID:
27369865
6.

Biological characterization of TAK-901, an investigational, novel, multitargeted Aurora B kinase inhibitor.

Farrell P, Shi L, Matuszkiewicz J, Balakrishna D, Hoshino T, Zhang L, Elliott S, Fabrey R, Lee B, Halkowycz P, Sang B, Ishino S, Nomura T, Teratani M, Ohta Y, Grimshaw C, Paraselli B, Satou T, de Jong R.

Mol Cancer Ther. 2013 Apr;12(4):460-70. doi: 10.1158/1535-7163.MCT-12-0657. Epub 2013 Jan 28.

7.

[Analysis of resolution of CNV (author's transl)].

Matsuda T, Teratani M, Kakigi S.

Shinrigaku Kenkyu. 1980 Oct;51(4):203-6. Japanese.

PMID:
7230542
8.

Variability in differentiation stages observed in a rat myeloid leukemia and its relation to human myeloid leukemia.

Okada K, Teratani M, Takahashi A, Mikami M, Okita H.

Nihon Ketsueki Gakkai Zasshi. 1977 Feb;40(1):87-106. No abstract available.

PMID:
267408
9.

A rat myeloid leukemia model of the human disease. Hematological characteristics of N-nitrosobutylurea-induced W/Fu rat leukemia L1504 and L1005.

Okada K, Teratani M, Takahashi A, Uchino H, Kajihara H.

Nihon Ketsueki Gakkai Zasshi. 1977 Feb;40(1):72-86. No abstract available.

PMID:
267407
10.

Chemotherapy of N-nitrosobutylurea-induced W/Fu rat myeloid leukemias.

Okada K, Teratani M, Takahashi A, Uchino H, Ohkita T.

Nihon Ketsueki Gakkai Zasshi. 1977 Feb;40(1):107-18. No abstract available.

PMID:
267404
11.

[Upper abdominal mass, bilateral abdominal pain, left cervical mass and pyrexia (blood pictures): (Richter's syndrome)].

Okita H, Teratani M, Fujimura K, Okada H, Kamata N.

Nihon Rinsho. 1977 Fall;35 Suppl 2:3138-9, 3504-5. Japanese. No abstract available.

PMID:
347124

Supplemental Content

Loading ...
Support Center